US FDA Picks Up The Pace Of Complete Response Letters Over June And July
Executive Summary
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
You may also be interested in...
Meeting Expectations: US FDA Communications Getting High Marks – Before COVID, At Least
FDA’s interactions with sponsors to support drug development activities are generally timely and effective – but industry still sees room for improvement in assuring ‘best practices’ are followed across all divisions.
Keeping Track: US FDA Has Clinical Questions For Tricida, Gilead And BioMarin; Enspryng And Winlevi Approved
The latest drug approval and decision news from the Pink Sheet’s US FDA Performance Tracker.
Two Major Drugs Pushed Back In One Day - The Return Of A Stricter US FDA?
Knock-backs for Gilead/Galapagos and BioMarin are a surprise, and could be a sign of the FDA reasserting its 'gold standard' approach to safety and efficacy.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: